SplashBIO Launches as an Independent Platform Company for Biomarker-Driven Clinical Trial EnrollmentSpun out from Splash Clinical, SplashBIO™ brings biomarker pre-screening to the front of the clinical trial — built to reduce screen failures and accelerate enrollment. The newly independent company will be at the Alzheimer’s Association International Conference (AAIC) 2026.
Splash Clinical Introduces SplashBIO™: A Biomarker Platform for Clinical TrialsA customizable platform that uses biomarker tests to accelerate enrollment, save money, and reduce screen failure rates.
